Research programme - small molecule therapeutics - Adlai Nortye

Drug Profile

Research programme - small molecule therapeutics - Adlai Nortye

Alternative Names: AN 1015; AN 2015; AN 3005; AN 4005; IDO inhibitor - Adlai Nortye; Indoleamine-pyrrole- 2,3-dioxygenase inhibitor - Adlai Nortye

Latest Information Update: 30 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Adlai Nortye
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Indoleamine-pyrrole 2,3-dioxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer
  • Research Acute myeloid leukaemia; Breast cancer; Head and neck cancer; Malignant melanoma; Mantle-cell lymphoma; Myelodysplastic syndromes; Non-small cell lung cancer

Most Recent Events

  • 28 Nov 2017 Early research in Acute myeloid leukaemia in China (unspecified route)
  • 28 Nov 2017 Early research in Breast cancer in China (unspecified route)
  • 28 Nov 2017 Early research in Head and neck cancer in China (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top